stockrow
Friday 6 November 2026
Export LIVN’s income statement to Excel — free account
LivaNova PLC
LIVN Healthcare Medical Devices
LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024.
- Revenue
- +9.88%
- EPS
- +27.4%
- Free cash flow
- −31.0%
- Total debt
- −31.2%
Quarter to September 2026, against a year earlier
90.71
0.43
−0.47%
Follow LIVN
Alert me
LivaNova PLC (LIVN) EBITDA
LivaNova PLC's EBITDA for fiscal 2025 was $282.1M, up 39.8% from $201.8M in fiscal 2024. Over the twelve months to 30 June 2026 it was $272.6M. Over the past ten years it has ranged from −$164.5M (fiscal 2018) to $282.1M (fiscal 2025) — the current reading is the highest in ten years. LivaNova PLC ranks 20th of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $282.1M | 39.79% |
| FY2024 | $201.8M | 1,668.40% |
| FY2023 | $11.4M | (91.34%) |
| FY2022 | $131.8M | 57.13% |
| FY2021 | $83.9M | — |
| FY2020 | −$161.6M | — |
| FY2019 | −$43.9M | — |
| FY2018 | −$164.5M | — |
| FY2017 | $211.2M | 29.49% |
| FY2016 | $163.1M | 70.87% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $72.6M | 17.44% |
| Mar 2026 | $61.8M | (1.98%) |
| Dec 2025 | $63.1M | (15.99%) |
| Sep 2025 | $75.1M | 0.19% |
| 44 more quarters | Free account |
Against its own ten years
Low −$164.5M
High $282.1M
Ten-year median
$95.5M
Current reading's percentile
100
EBITDA against peers
| Company | EBITDA |
|---|---|
| ITGR Integer Holdings Corporation compare | $296.5M |
| HAE Haemonetics Corporation compare | $273.8M |
| LIVN LivaNova PLC | $272.6M |
| BRKR Bruker Corporation compare | $158.7M |
| NEOG Neogen Corporation compare | $116.5M |
| IRTC iRhythm Holdings, Inc. compare | $1.5M |
| AXGN AxoGen, Inc. compare | −$4.1M |
| TXG 10x Genomics compare | −$40.4M |
| BIO Bio-Rad Laboratories, Inc. compare | −$61.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on LIVN
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement